AJIC: American Journal of Infection Control
Volume 37, Issue 9 , Pages 741-745 , November 2009

Multidrug-resistant Escherichia coli bacteremia in cancer patients

  • Karen J. Vigil, MD

      Affiliations

    • University of Texas at Houston-Medical School, Houston, TX
    • ,
  • Javier A. Adachi, MD

      Affiliations

    • University of Texas-M.D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationAddress correspondence to Javier A. Adachi, MD, 1400 Pressler, Unit 1460, Houston, TX 77030.
    • ,
  • Halim Aboufaycal, MD

      Affiliations

    • University of Texas at Houston-Medical School, Houston, TX
    • ,
  • Ray Y. Hachem, MD

      Affiliations

    • University of Texas-M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Ruth A. Reitzel, BS

      Affiliations

    • University of Texas-M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Ying Jiang, MS

      Affiliations

    • University of Texas-M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Jeffrey J. Tarrand, MD

      Affiliations

    • University of Texas-M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Roy F. Chemaly, MD

      Affiliations

    • University of Texas-M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Gerald P. Bodey, MD

      Affiliations

    • University of Texas-M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Kenneth V. Rolston, MD

      Affiliations

    • University of Texas-M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Isaam Raad, MD

      Affiliations

    • University of Texas-M.D. Anderson Cancer Center, Houston, TX

References 

  1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317
  2. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, et al. Bacteremia and antibiotic resistance of its pathogen reported in England and Wales between 1990 and 1998: trend analysis. BMJ. 2000;320:213–216
  3. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis. 2000;30:454–460
  4. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490–494
  5. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 to June 2001. Am J Infect Control. 2001;29:404–421
  6. Diekema DJ, Coffman SL, Marshall SA, Beach ML, Rolston KV, Jones RN. Comparison of activities of broad-spectrum β-lactam compounds against 1128 gram-positive cocci recently isolated in cancer treatment centers. Antimicrob Agents Chemother. 1999;43:940–943
  7. Fridkin SK, Steward CD, Edwards J, Pryor ER, McGowan JE, Archibald LK. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999;29:245–252
  8. NNIS System . National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–485
  9. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885–888
  10. Lautenbach E, Strom BL, Nachamkin I, Bilker WB, Marr AM, Larosa LA, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis. 2004;38:655–662
  11. Cattaneo C, Quaresmini G, Casari S. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant E coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61:721–728
  12. Peralta G, Sánchez MB, Garrido JC, De Benito I, Cano ME, Martínez-Martínez L, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with E coli bacteraemia. J Antimicrob Chemother. 2007;60:855–863
  13. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, et al. Survey of bloodstream infections due to gram-negative bacilli frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis. 1999;29:595–607
  14. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis. 2000;30:454–460
  15. Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. Multidrug-resistant urinary tract isolates of E coli prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother. 2001;45:1402–1406
  16. Oteo J, Campos J, Baquero F. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System. J Antimicrob Chemother. 2002;50:945–952
  17. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–998
  18. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987
  19. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979–995
  20. Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis. 2001;33:48–53
  21. McDonald LC, Chen FJ, Lo HJ, Yin HC, Lu PL, Huang CH, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother. 2001;45:3084–3091
  22. Richard P, Delangi MH, Raffi F, Espaze E, Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant, gram-negative bacilli from gastrointestinal flora. Clin Infect Dis. 2001;32:162–166
  23. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Enterobacteriaceae M7MIC. Wayne PA: Clinical and Laboratory Standards Institute; 2008;pp 98-101
  24. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24:111–118
  25. Baum HV, Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection. 2000;28:278–281
  26. Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer. 2003;97:419–424
  27. Lautenbach E, Fishman NO, Bilker WB, Castiglioni A, Metlay JP, Edelstein PH, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med. 2002;162:2469–2477
  28. Tancrede CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis. 1985;152:99–103
  29. Owens WE, Berg RD. Bacterial translocation from the gastrointestinal tract of thymectomized mice. Curr Microbiol. 1982;7:169–174
  30. Steffn EK, Berg RD. Relationship between cecal population levels of indigenous bacteria and translocation to the mesenteric lymph nodes. Infect Immun. 1983;39:1252–1259
  31. Bliklevens NM. Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol. 2005;17:605–610

 Supported by discretionary funds, with no external or private financial support. KJV and JAA contributed equally to this work.

 An abstract version of this paper was presented at the 45th Annual Meeting of the Infectious Diseases Society of America (IDSA) on October 2007.

 Conflicts of interest: None to report.

PII: S0196-6553(09)00429-5

doi: 10.1016/j.ajic.2009.02.002

AJIC: American Journal of Infection Control
Volume 37, Issue 9 , Pages 741-745 , November 2009

Article Tools